

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 392.1001

SERIAL NO.: 10/526,508

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Hiroyuki ABURATANI et al.

FILING DATE: September 4, 2003

GROUP: 1642

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							
	AJ							
	AK							
	AL							
	AM							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/T.D./	AN	ZHU Z-W ET AL: "Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders" GUT, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 48, 17 October 2001 (2001-10-17), pages 558-564, XP002959808 ISSN: 0017-5749
/T.D./	AO	KLEEFF J H ET AL: "Glypican-3 is a potential tumor marker for hepatocellular carcinoma" GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 118, no. 4, SUPPL 2, PART 1, 2000, page A261, ABSTRACT1501, XP002959809 ISSN: 0016-5085
/T.D./	AP	NACKAERTS K ET AL: "HEPARAN SULFATE PROTEOGLYCAN EXPRESSION IN HUMAN LUNG-CANCER CELLS" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 74, 1997, pages 335-345, XP002925654 ISSN: 0020-7136

EXAMINER /Minh Tam Davis/ (02/04/2008)

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.